Skystar Bio-Pharma (NASDAQ:SKBI)

The GeoTeam ® is re-coding Skystar Bio-Pharma as a Geo special situation play as opposed to a Geo Bargain.  The Company's 2008 non-GAAP EPS growth rate of 16.10% is below the Geo Team's ® preferred 30% minimum.  However, since the company achieved non-GAAP EPS growth of 75% in its 2009 first quarter and due to its consistent non-GAAP EPS growth track record, the company is also being added to the Geo Bargain On The Radar list.   Furthermore, the company is taking actions to increase the manufacturing capacity of its veterinary  vaccine division. The veterinary vaccine division currently contributes the least to Skystar Bio-Pharma's revenues, but has some of the more exciting growth prospects, offering the opportunity for significant growth in the future.  The company is also selling at an exceptionally low PEG ratio.  See potential valuation scenarios.  More details to follow.